Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Regulatory dendritic cells: profiling, targeting, and therapeutic application

Regulatory dendritic cells: profiling, targeting, and therapeutic application Downloaded from https://pdfs.journals.lww.com/co-transplantation by BhDMf5ePHKZxZb3ruX4b9cKfbT5h3bp+v9gTtSlrchDWvVTxyN8Hif2P/rPZfAxb8td684/2m6Qu95wFG/gkPJpea77fq0P0pQcHA4l/5n1oEJVqkRegcfAJ00vGdVVZ on 04/30/2020 REVIEW URRENT Regulatory dendritic cells: profiling, targeting, and PINION therapeutic application a,b a Angus W. Thomson and Mohamed B. Ezzelarab Purpose of review There is currently increased focus on improved understanding of how dendritic cell tolerogenicity is determined and maintained, and on their therapeutic potential. We review recent progress in profiling of regulatory dendritic cells (DCreg), innovative approaches to enhancing dendritic cell tolerogenicity in situ, ex-vivo generation of DCreg and initial clinical testing of these cells in organ transplantation. Recent findings ‘‘Omics" studies indicate that the distinctive properties of DCreg are the result of a specific transcriptional program characterized by activation of tolerance-enhancing genes, rather than the retention of an immature state. In situ dendritic cell-directed targeting of nanovesicles bearing immune regulatory molecules can trigger in-vivo expansion of Ag-specific regulatory cells. Innovative approaches to ex-vivo modification of dendritic cells to enhance their regulatory function and capacity to migrate to secondary lymphoid organs has been described. Cross-dressing (with donor major histocompatibility complex molecules) of graft-infiltrating host dendritic cells that regulate antidonor T-cell responses has been implicated in ‘‘spontaneous" liver transplant tolerance. Clinical trials of DCreg therapy have begun in living donor renal and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Head & Neck Anesthesia Wolters Kluwer Health

Regulatory dendritic cells: profiling, targeting, and therapeutic application

Loading next page...
 
/lp/wolters-kluwer-health/regulatory-dendritic-cells-profiling-targeting-and-therapeutic-99e9FiB0MN

References (68)

Publisher
Wolters Kluwer Health
eISSN
2475-5028
DOI
10.1097/MOT.0000000000000565
Publisher site
See Article on Publisher Site

Abstract

Downloaded from https://pdfs.journals.lww.com/co-transplantation by BhDMf5ePHKZxZb3ruX4b9cKfbT5h3bp+v9gTtSlrchDWvVTxyN8Hif2P/rPZfAxb8td684/2m6Qu95wFG/gkPJpea77fq0P0pQcHA4l/5n1oEJVqkRegcfAJ00vGdVVZ on 04/30/2020 REVIEW URRENT Regulatory dendritic cells: profiling, targeting, and PINION therapeutic application a,b a Angus W. Thomson and Mohamed B. Ezzelarab Purpose of review There is currently increased focus on improved understanding of how dendritic cell tolerogenicity is determined and maintained, and on their therapeutic potential. We review recent progress in profiling of regulatory dendritic cells (DCreg), innovative approaches to enhancing dendritic cell tolerogenicity in situ, ex-vivo generation of DCreg and initial clinical testing of these cells in organ transplantation. Recent findings ‘‘Omics" studies indicate that the distinctive properties of DCreg are the result of a specific transcriptional program characterized by activation of tolerance-enhancing genes, rather than the retention of an immature state. In situ dendritic cell-directed targeting of nanovesicles bearing immune regulatory molecules can trigger in-vivo expansion of Ag-specific regulatory cells. Innovative approaches to ex-vivo modification of dendritic cells to enhance their regulatory function and capacity to migrate to secondary lymphoid organs has been described. Cross-dressing (with donor major histocompatibility complex molecules) of graft-infiltrating host dendritic cells that regulate antidonor T-cell responses has been implicated in ‘‘spontaneous" liver transplant tolerance. Clinical trials of DCreg therapy have begun in living donor renal and

Journal

Journal of Head & Neck AnesthesiaWolters Kluwer Health

Published: Jul 1, 2018

There are no references for this article.